Medicare hits $200 billion in gross drug spend: Who gets the blame?
Ben LinkMedicare, Part D, Brand drugs, Generic drugs, Specialty, DIR fees, Rebates, PBM, Eliquis, Revlimid, Xarelto, Januvia, Trulicity, Imbruvica, Lantus, Jardiance, Humira, Ibrance, NADAC, atorvastatin, WAC
International reference pricing: Discounts Down Under far surpass U.S. drug price concessions
Ben LinkAustralia, International pricing, PBM, NADAC, Eliquis, Rebates, Advair, Fluticasone, Gleevec, Imatinib, Part D, Part B, Aetna, Albuterol
The Flawed Design of Medicare Part D: A Copaxone Case Study
Ben LinkCopaxone, glatiramer, Medicare, Part D, PBM, specialty drugs, Gleevec, ACA, Drug prices, Teva, Mylan, Sandoz, Deductible, Rebates, DIR fees